[Coating material of parlene C as encapsulation material for biomedical micro-implants]. / Untersuchungen zur Abscheidung von Parylen C als Kapselungsmaterial für Biomedizinische Mikroimplantate.

Biomedical microsystems attain to contact with environments like blood, ephitHelium and saline solutions therefore they need an encapsulation. Parylene seems to be a suitable polymer to cover the implants and protect them against moisture and aggressive environment. This paper describes the characterisation of Parylene C coatings and its possibilities to protect implants. Beside the encapsulation of biomedical microsystems the manufacturing of fexible electrodes and the cytotoxicity behavior of RIE etched Parylene layers was investigated.

Purified chicken growth hormone (GH) and a human pancreatic GH-releasing hormone increase body weight gain in chickens.

Purified chicken GH (cGH) and a synthetic human GH-releasing hormone (hpGRF) were tested for the ability to improve growth performance in chickens. Purified cGH was given to 4-week-old cockerels at 5, 10, and 50 micrograms/day for 14 days via daily iv injection. Body weights of chickens receiving 5 and 10 micrograms/day cGH were significantly increased at 6 days by 13.5% and 11.2%, respectively, relative to control values. At 14 days, body weights averaged 8.1% and 7.7% greater than controls, but these values were not statistically significant. There was a slight stimulation of body weight gain in chickens receiving 50 micrograms/day cGH. In general, cGH produces a transient stimulation of body weight gain in chickens. hpGRF was also given to 4-week-old cockerels for 14 days via daily iv injection at 0.1, 1.0, and 10.0 micrograms/day. hpGRF at 0.1 microgram/bird daily increased body weight on day 14 (9.1% over the control value). The stimulating effects of hpGRF on body weight are also transient. The effects of cGH on serum somatomedin-C (SM-C) were examined. Serum SM-C concentrations were significantly elevated 24 and 36 h after injection of cGH. In conclusion, purified cGH and hpGRF appear to have some growth-promoting activity. The stimulatory effect of hpGRF on weight gain may be mediated via GH, and the stimulatory effect of cGH could be mediated through SM-C.

Effects of thyrotropin-releasing hormone and a thyrotropin releasing hormone analog on growth and selected plasma hormones in lambs.

An 8-wk growth trial was conducted to assess the effects of continuous infusion of thyrotropin-releasing hormone (TRH) and an active TRH analog less than Aad-His-Pro-NH2 (the less than Aad is L-pyro-alpha-aminoadipic acid) on growth trial performance, carcass composition and hormone profiles of growing lambs. Both drugs were infused at 600 micrograms X lamb -1 X d -1 with 16 lambs/treatment. Both TRH and less than Aad-His-Pro-NH2 decreased average daily gain (ADG; P less than .01) and increased feed conversion (FC; P less than .01) compared with saline infused controls. Average daily feed intake was not altered. Carcasses of lambs given TRH or less than Aad-His-Pro-NH2 contained fewer kilograms of moisture (P less than .05) and appeared to contain fewer kilograms of protein. Thyrotropin-releasing hormone and less than Aad-His-Pro-NH2 increased thyroid gland weights (P less than .05), but pituitary gland weights were not different. Plasma thyrotropin (TSH) concentrations were increased by both drugs compared with control lambs, peaking at 4 to 7 d after initiating infusion. However, by 14 d, TSH concentrations returned to control levels. Triiodothyronine (T3) and thyroxine (T4) were elevated by both drugs over the entire 8-wk trial, with peak levels reached at 10 d and maintained for the duration of the study. Both TRH and less than Aad-His-Pro-NH2 increased prolactin over the entire period. Growth hormone levels were not altered by either drug. The effects of less than Aad-His-Pro-NH2 infusion on growth trial performance, carcass composition and hormone profiles of growing lambs were very similar to TRH. The negative effects of TRH and less than Aad-His-Pro-NH2 infusion on ADG, FC and carcass protein appear to be the result of elevated T3 and T4 levels.

Effects of exogenous growth hormone and diethylstilbestrol on growth and carcass composition of growing lambs.

An 8-wk growth trial was conducted to assess the effects of ovine growth hormone (oGH; 7 mg/d, sc) on growth performance and carcass composition of normal, growing wether lambs. Diethylstilbestrol (DES; .1 mg/d, sc) and control lambs were included for comparisons. Plasma oGH levels at 8 wk were 1.9, 5.5 (P less than .05) and 138.1 ng/ml (P less than .001) for controls, DES and oGH lambs, respectively. Diethylstilbestrol did not increase plasma oGH until the fourth week. The oGH improved feed conversion 7.4% (FC; P less than .05), but did not alter average daily gain (ADG) or feed intake (ADF). Diethylstilbestrol increased ADG 15.3% (P less than .05) and improved FC 16.1% (P less than .01), with no effect on ADF. The primary effect of oGH on carcass composition was to decrease the quantity of fat 8.9% (P less than .05). In addition, oGH may have increased protein 6.5% (P less than .10) and moisture 4.0% (not significant). Diethylstilbestrol increased the quantity of carcass protein 10% (P less than .01) and moisture 8.7% (P less than .05), with no effect on fat. In these studies, the primary effect of exogenous oGH on normal, growing lambs was to reduce carcass fat, which may account for the observed improvement in FC. Diethylstilbestrol, at 1/70th of the oGH dose, was superior to oGH for improving FC (P less than .05) and ADG (P less than .10). Improvements in body weight of the lambs given DES were observed 2 wk before an increase in plasma oGH. In addition, DES, unlike exogenous oGH, did not alter the quantity of carcass fat. These observations do not support the concept that the mode of action of DES is through increased GH secretion.